DOI: 10.33880/ejfm.2026150304 ISSN: 2147-3161

Antioxidant Mediated Neuroprotection in Psychiatric Disorders: A Redox Based Pharmacotherapeutic Perspective

Satish Kumar Basattikoppalu Puttegowda, Mohith Shivaramu, Pooja Anjanappa

Emerging findings indicate oxidative stress contributes to psychiatric disorders like schizophrenia, bipolar, major depressive disorder, and anxiety disorders. This is due to disrupted antioxidant defense, increased reactive oxygen species, mitochondrial issues, and neuroinflammation. These lead to neuronal apoptosis, synaptic dysfunction, and degeneration. Antioxidants, both endogenous and exogenous, are crucial for neuronal protection by restoring redox balance, enhancing mitochondrial resilience, and reducing inflammation. Preclinical studies show antioxidants like N-acetyl cysteine, vitamins E, C, omega-3 fatty acids, curcumin, resveratrol, and coenzyme Q10 protect neurons, enhance neuroplasticity, and improve cognitive, behavioral outcomes in psychiatric models. Clinical studies support these findings, especially N-acetyl cysteine in schizophrenia and bipolar disorder, improving negative symptoms, mood stabilization, and cognitive function. Omega-3s benefit depressive disorders, while vitamin E and polyphenols show some oxidative-related symptom relief in psychiatric disorders. Despite supportive evidence of antioxidants as treatment, findings are mixed, and response varies due to dosing, treatment duration, disease severity, and biomarker profiles. The evidence supports the adoption of antioxidants as a supplementary therapy to existing pharmacotherapy for most psychiatric illnesses with strong oxidative and/or inflammatory components. However, there are many inconsistencies and varying clinical outcomes associated with adjunct antioxidant therapies and limited biomarker studies; therefore, large scale randomized controlled trials are necessary to provide solid evidence for their use. Future studies should also expand on the area of personalized antioxidant therapy and how it works alongside standard psychotropic medications and identifies novel redox-based therapeutic targets to enhance neuroprotection and promote longer-term functional recovery from these illnesses.